The American Society of Clinical Oncology said it opposes “right-to-try” laws that allow terminally ill patients to request access to investigational drugs directly from manufacturers, bypassing a layer of review, where FDA assesses the available data to review and benefits of the treatment on behalf of the patient.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
